ATRX and central nervous system cancer: A panel of antibodies, including IDH1R132H, ATRX, and P53, may be useful in routine practice for differentiating between grade 2, 3, and 4 astrocytomas, grade 2, 3 oligodendrogliomas, glioblastomas, and NEC gliomas.